Home >  Registry
     
 
Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Trial information

A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Status: Completed

Protocol number: NA17101

Sponsor: Hoffmann-La Roche Inc

Company division: Pharmaceutical

Official Scientific Title: A randomized, open-label study of the effect of subcutaneous Mircera on hemoglobin level/correction in anemic patients with Stage IIIB or IV non-small-cell lung carcinoma receiving antineoplastic therapy

Brief summary: This study will assess the efficacy and safety of different subcutaneous (sc) doses and dosing frequencies of Mircera in patients with non-small cell lung cancer (NSCLC) and anemia who are receiving chemotherapy. The anticipated time on study treatment is less than 3 months and the target sample size is 100-500 individuals. Target sample size is 210.

Study phase: II

Study type: Interventional; Treatment; Randomized; Open Label; Active; Parallel; Safety/Efficacy study

Condition: Anemia

Intervention type: Drug

Intervention name: methoxy polyethylene glycol-epoetin beta[Mircera]

Primary outcome: 1. Efficacy:Time-adjusted average hemoglobin value between baseline and end of initial treatment

Key secondary outcomes: 1. Efficacy: Change from baseline in Hb, Hct, reticulocyte count, Hb and hematopoietic response, transfusion requirements Safety: Vital signs, AEs, lab values

Inclusion criteria:

  • adult patients >=18 years of age;
  • anemia;
  • NSCLC;
  • receiving chemotherapy.

Exclusion criteria:

  • women who are pregnant, breastfeeding or using unreliable birth control methods;
  • administration of another investigational drug in the 30 days preceding the first dose of study medication.

Gender: Males or Females

Age limits: Min: 18 Years Max: N/A (No limit)

Accepts healthy volunteers: No

Trial registration date: 05/23/2005

Date last updated: 9/29/2008


Link to trial result

This trial was conducted at the following locations:

Australia

  • Adelaide
  • Brisbane
  • Melbourne

Belgium

  • Liege

Canada

  • Surrey, BC
  • Vancouver, BC
  • Ottawa, ON
  • Montreal, QC
  • Sainte-Foy, QC

China

  • Hong Kong

Germany

  • Gauting
  • Grosshansdorf
  • Hamburg
  • Heidelberg
  • Trier

Hungary

  • Budapest
  • Nyiregyhaza
  • Szombathely

Italy

  • Genova
  • Parma
  • Sassari

Lithuania

  • Kaunas
  • Klaipeda

Mexico

  • Chihuahua
  • Mexico City

Panama

  • Panama City

Poland

  • Olsztyn
  • Otwock
  • Poznan
  • Warszawa

Spain

  • Barcelona
  • Madrid

Taiwan

  • Kueishan
  • Taipei

United States

  • Bakersfield, CA
  • Fullerton, CA
  • Greenbrae, CA
  • Long Beach, CA
  • Los Angeles, CA
  • Northridge, CA
  • Oceanside, CA
  • Pomona, CA
  • Porterville, CA
  • Santa Barbara, CA
  • Vista, CA
  • Colorado Springs, CO
  • Des Moines, IA
  • Tupelo, MS
  • Great Falls, MT
  • Rochester, NY
  • Rockville Centre, NY
  • Hickory , NC
  • Bismarck, ND
  • Canton, OH
  • Kingston , PA
  • Philadelphia, PA
  • Aiken, SC
  • Memphis , TN
  • Houston, TX
  • Bennington, VT
  • Tacoma, WA

To contact Roche for more information on this trial please complete the email form below. Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the studies, please have your healthcare provider contact us via this website, and they will be provided with the relevant clinical trial information.

Country*
Are you a:*
Subject*
Last Name*
First Name*
Telephone
E-mail*

your email address is needed for us to reply